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It is well known that Neuroblastoma (NB) patients whose tumors have an undifferentiated
histology and a transcriptome enriched in cell cycle genes have a worse prognosis. This
contrasts with the good prognoses of patients whose tumors have histologic evidence
of differentiation and a transcriptome enriched in differentiation genes. Tumor cell lines
from poor prognosis, high-risk patients contain a number of genetic alterations, including
ampliﬁcation of MYCN, 1pLOH, and unbalanced 11q or gains of Chr 17 and 7, and exhibit
uncontrolled growth and an undifferentiated phenotype in in vitro culture.Yet treatment of
such NB cell lineswith retinoic acid results in growth control and induction of differentiation.
This indicates that the signaling pathways that regulate cell growth and differentiation
are not functionally lost but dysregulated. Agents such as retinoic acid normalize the
signaling pathways and impose growth control and induction of differentiation. Recent
studies in embryonic stem cells indicate that polycomb repressor complex proteins (PRC1
and PRC2) play a major role in regulating stem cell lineage speciﬁcation and coordinating
the shift from a transcriptome that supports self-renewal or growth to one that speciﬁes
lineage and controls growth. We have shown that in NB, the PRC2 complex is elevated
in undifferentiated NB tumors and functions to suppress a number of tumor suppressor
genes.This study will review the role of MYC genes in regulating the epigenome in normal
development and explore how this role may be altered during tumorigenesis.
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MYCN AND NEUROBLASTOMA
Ever since MYCN was discovered to be the commonly ampliﬁed
sequence in neuroblastoma (NB) tumors some 30 years ago, the
mechanisms by which it contributes to NB tumorigenesis and
strategies to target it have been intensively investigated (Schwab
et al., 1983). The ﬁnding that MYCN ampliﬁcation in NB tumors
identiﬁed patients with the worst prognoses led to the integra-
tion of MYCN copy status into risk stratiﬁcation protocols for
treatment (Goto et al., 2001). MYCN was the ﬁrst oncogene inte-
grated into clinical practice and is still used to stratify patients for
therapy. One of the early attempts to target MYCN evolved from
the ﬁnding that retinoids inhibited MYCN expression as part of
the widespread transcriptional changes retinoids induced in NB
cells which resulted in tumor cell growth arrest and differentiation
(Thiele et al., 1985). Later retinoids were integrated into the con-
solidation phase of high-risk therapeutic protocols and found to
increase patient overall survival (Park et al., 2009). However, the
molecular mechanisms by which MYCN stimulates tumorigenesis
have remained a mystery.
Functionally MYC family genes (MYC, MYCN, and MYCL)
have been implicated in nearly every biologic process evaluated.
Evidence indicates that MYC and MYCN are functionally inter-
changeable with MYCN having a more restricted spatial and
temporal role during development (Malynn et al., 2000). In this
review, it is assumed that what is known for the molecular mech-
anisms of MYC action can be extrapolated to MYCN, unless
otherwise noted. This review will focus on MYC interaction
with the epigenome especially with regards to regulation of gene
transcription and translation.
MYC, CHROMATIN STRUCTURE, AND GENE TRANSCRIPTION
MYC is a member of a basic helix-loop-helix transcription-
leucine zipper (bHLH-Zip) factor familywhosemembers dimerize
with MAX and bind to speciﬁc DNA sequences called E-boxes
(Figure 1). Based on studies using naked DNA, two prevailing
views emerged as to how MYC affects transcription: (1) a direct
mechanism in which MYC/MAX dimers upon binding to E-boxes
recruit higher order chromatin complexes that activate or repress
transcription or (2) an indirect mechanism in which MYC/MAX
dimers compete with other bHLH-Zip transcription factors for
E-boxbindingtoaltertargetgeneactivity.Insearchingforacommon
MYC target signature investigators have proposednumerous target
signatures in different cellular contexts, but none have proven true
in all cellular contexts (Cotterman et al., 2008; Souﬁ et al., 2012).
Recent studies assessing global transcription regulated by MYC
in normal cells as well as in tumor cells reveal that MYC acts
as a direct ampliﬁer of transcriptionally active genes and does
not directly induce de novo gene transcription or directly silence
expressed genes (Lin et al., 2012; Nie et al., 2012; Souﬁ et al.,
2012). MYC function as a transcriptional ampliﬁer is supported
by the lack of a classical transcriptional gene signature in numer-
ous contexts, although, the precise molecular mechanisms that
mediate transcriptional ampliﬁcation remains to be elucidated
(Knoepﬂer et al., 2006;Nie et al., 2012). Given, the lackof a classical
transcriptional signature and the apparent dependence of MYC on
chromatin context, studies have suggested MYC elicits its function
epigenetically (Guccione et al., 2006; Souﬁ et al., 2012).
Within the last decade there has been a dramatic shift in our
understanding of mechanisms of transcriptional regulation. This,
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FIGURE 1 | Diagram of MYC functional regions. In the region of the
transcriptional activation domain (TAD) the MYC Box II (MBII) bindsTRRAP
containing complexes of proteins that may also contain GCN5. It is also felt
that p-TEFb, Tip60, and a number of other transcriptional regulatory factors
can bind to this region. Determinants of which factors bind remain to be
resolved. The bHLH region binds E-box containing regions of DNA. MYC
dimerizes with other bHLH containing transcription factors via a
carboxy-terminal leucine zipper (Zip) region.While MYC recruits HATs such as
GCN5 and CBP/p300 which are known to acetylate lysine residue on histone
tails, these HATs are also known to acetylate (Ac) MYC which affects its
stability by blocking or competing with ubiquitin ligases that target MYC for
degradation.
coupledwith the ability to query the entire transcriptomehas given
us a broader understanding of how MYC affects transcription. In
order to appreciate MYC’s role in epigenetic regulation we must
ﬁrst step back and look at the problem of higher order chromatin
structure and regulation of gene transcription.
The necessity to compact some 2 m worth of DNA into the
10–20 μm nucleus of a cell has resulted in the evolution of a
dynamic packaging system in eukaryotes that allows for the regu-
lated sequestration or exposure of stretches of DNA. DNA (about
146 bp) is wrapped twice around an octamer of histone proteins
(H3, H4, H2A, and H2B) and stabilized by histone H1, form-
ing the nucleosome, the basic unit of chromatin (Figure 2A).
Nucleosomes are then joined by a stretch of linker DNA (20 bp).
When DNA is tightly complexed to histones, transcription is
silenced. Activation of gene transcription requires loosening of
DNA–histone interactions to enable access by transcription fac-
tors, the melting of the DNA that enables access of the basal
transcription machinery including RNA polymerase II (Pol II)
and the sliding of the nucleosomes to enable transcriptional elon-
gation. The accessibility of DNA to DNA binding transcription
factors is dynamically regulated by post-translational modiﬁca-
tions to histone“tails”such asmethylation (methyltransferases and
demethylases), acetylation (acetyltransferases and deacetylases),
phosphorylation (kinases and phosphatases), ADP-ribosylation,
and ubiquitination (Figure 2A).
The diversity of histone post-translational modiﬁcations led
to the proposal that they represented a “histone code” that was
written and erased by various enzymes or protein complexes and
functioned to regulate the accessibility of DNA for DNA repli-
cation or gene transcription (Strahl and Allis, 2000). In this
model, the combinatorial power of the various modiﬁcations
would enable the integration of stimuli from numerous differ-
ent environmental signaling pathways and serve as a ﬁnal readout
directing gene activation or suppression. The model also seems
to reconcile apparent situational discrepancies in which post-
translation modiﬁcations such as acetylation may be associated
with gene activation or suppression depending on cell lines or
context. While global histone acetylation may correspond to active
transcription, downstream effectors activated may instigate sup-
pression at certain loci. Not only do the modiﬁcations affect the
charge of the histones and their interactionwithDNAbut they also
can be read or serve as docking sites for other proteins. For exam-
ple, acetylated histones serve as docking sites for bromodomain
(Br) containing proteins (Dhalluin et al., 1999; Dey et al., 2003).
Thus, the histone code imparts a tertiary level of genomic con-
trol beyond the DNA sequence and corresponding transcription
factors.
MYC AND CHROMATIN REMODELING
HISTONE ACETYLATION
Nucleosomal elements of the epigenome not only control DNA
accessibility, but also function as a physical barrier to transcription
that transcription factors and chromatin remodeling complexes
must overcome to initiate and maintain transcription (Zaret and
Carroll, 2011; Bintu et al., 2012). Emerging evidence suggest tran-
scription factors and chromatin remodeling complexes coordinate
to access target DNA loci and conversely silence loci when the gene
product is no longer desired (Cirillo et al., 2002; Filion et al., 2010;
Zaret and Carroll, 2011; Souﬁ et al., 2012). While epigenetic func-
tions of MYC are still being elucidated, recent studies demonstrate
MYC may direct epigenetic changes at target loci by relaxing the
nucleosomal barrier making it more permissive for subsequent
transcription.
When MYC function was ﬁrst being described over 20 years
ago, it was noted that MYC preferentially binds to “open” nucleo-
somes and DNase sensitive loci that we now know characterize
euchromatin (Klempnauer, 1989; Telford and Stewart, 1990).
Euchromatinwas known to correlate with active transcription, but
how MYC modulated this effect was unclear. As studies emerged
explicating histone modiﬁcations, it was shown that MYC recruits
macromolecular complexes containing chromatin remodelers to
its target loci (McMahon et al., 1998, 2000; Cheng et al., 1999;
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FIGURE 2 | (A) Compacted heterochromatin is characterized by speciﬁc
methylation of H3K9 and H3K27 is often correlated with decreased
transcription. The EZH2 component of PRC2 contains the H3K27methylase
while EHMT2 or G9a contains the H3K9 methylase. The methylation
status of these amino acids is regulated by demethylases such as LSD1,
JMJD2, and UTX. The subsequent acetylation (Ac) of H3K9 by GCN5 and
H3K27 by CBP/p300 are associated with relief of gene suppression.
(B) MYC recruits TRRAP to target loci to mediate MYC binding to histone
acetyltransferases (HATs). Recruited HATs acetylate histone components to
promote transcription. Conversely, MAD recruits Sin3 to target loci to mediate
MAD binding to histone deacetylases (HDACs). Histone deacetylation allows
for methylation events leading to transcriptional silencing. (C) Via
TRRAP, MYC is able to recruit HATs GCN5, TIP60, and CBP/p300
to target loci to relax the nucleosomal barrier making DNA more
accessible to transcriptional machinery and making the nucleosome
more permissive for transcription. (D) MYC can also bind to TBP
suggesting it can recruit elements of the transcriptional pre-initiation
complex to initiate transcription. To maintain transcription MYC recruits
p-TEFb and BRD4 to catalyze promoter pause release and transcriptional
elongation. BRD4, as well as GCN5 and CBP, have bromodomains
(Br) that recognize acetyl-lysines which has proven necessary for proper
function.
Wood et al., 2000; Frank et al., 2003; Vervoorts et al., 2003). Evi-
dence suggested MYC elicited its oncogenic effects by binding
to cofactors via a highly conserved amino acid domain in its
N-terminus transactivation domain called MYC Box II (MBII;
Figure 1; Stone et al., 1987). Seminal work discovered that a novel
protein, transformation/transcription domain-associated protein
(TRRAP), binds to MYC at MBII and deletion of MBII or inhibi-
tion of TRRAPabrogatedMYC inducedoncogenic transformation
(McMahon et al., 1998). These results implicated TRRAP as an
essential cofactor for MYC function, but TRRAP itself had no
histone remodeling function (Figure 2B).
Further work revealed that, via TRRAP, MYC was able to
recruit histone acetyltransferases (HATs), GCN5 and Tip60 to its
targets. GCN5 and Tip60 were ﬁrst identiﬁed in Saccharomyces
cerevisiae as members of the SAGA and NuA4 HAT complexes,
respectively, and have been shown to have similar function in
mammals (McMahon et al., 2000; Frank et al., 2003; Figure 2C).
Concordantly, in embryonic stem cells (ESCs) MYC has been
shown to elicit its transcriptional induction through the mam-
malian NuA4 complex and in neural stem cells MYCN and GCN5
have similar transcriptional signatures (Kim et al., 2010; Martinez-
Cerdeno et al., 2012). Both GCN5 and Tip60 have HAT activity,
but differ in their histone substrate speciﬁcity. GCN5 preferen-
tially acetylates H3, H2B, while Tip60 preferentially acetylates
H4 and H2A (Allard et al., 1999; McMahon et al., 2000). In
addition, Myc has also been shown to bind to TATA-binding
protein (TBP), a member of the transcriptional pre-initiation
complex, and cAMP-response-element-binding protein (CBP),
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one half of the CBP/p300 coactivator complex, which has HAT
activity and scaffolding functions (McEwan et al., 1996; Ogryzko
et al., 1996; Chan and La Thangue, 2001; Vervoorts et al., 2003;
Figure 2C). Although TBP has no HAT activity, its binding to
MYC suggests MYC is able to recruit Pol II machinery to activate
transcription (Figure 2D). Therefore, through its binding part-
ners MYC is able to regulate the chromatin landscape to exert its
function.
The functional impact of acetylated histones is a general reduc-
tion to the nucleosomal barrier, promoting cofactor binding, and
increased Pol II passage, thereby increasing transcriptional activ-
ity (Knoepﬂer et al., 2006; Bintu et al., 2012; Figure 2D). GCN5
and Tip60 function to promote transcription by their acetyltrans-
ferase activity, but it is not limited to histones. It has also been
demonstrated that MYC is a substrate of acetyltransferase activ-
ity. GCN5, Tip60, and CBP/p300 all acetylate MYC (Figure 1;
Patel et al., 2004). Acetylation of MYC stabilizes the protein and
prevents ubiquitin-mediated degradation thereby increasing MYC
transcriptional latency (Figure 1;Vervoorts et al., 2003; Patel et al.,
2004). These results suggest that not only are the HATs MYC
recruits to its target loci essential transcriptional cofactors, but
also essential to maintain MYC function in a pseudo-feed-forward
mechanism.
Convincingly,MYC has been shown to recruit chromatin mod-
iﬁers to elicit its transcriptional ampliﬁer function. Less well
resolved is how ampliﬁed MYC transcripts further act as down-
stream effectors. In neural progenitors, MYC has been shown to
stimulate the transcription of GCN5, which endows MYC with
a feed-forward loop stimulating increased transcriptional activ-
ity and its own stability (Knoepﬂer et al., 2006). It is of interest
that in neural progenitors both GCN5 and MYCN conditional
knockouts have impaired precursor proliferation in vitro and are
marked by microcephaly. Moreover, the transcriptomes of GCN5
and MYCN conditional knockouts exhibit overlap in a signiﬁ-
cant number of repressed and activated genes that commonly are
involved in signaling and neural differentiation (Martinez-
Cerdeno et al., 2012).
ATP-DEPENDENT CHROMATIN REMODELING
In addition to HAT recruitment via MBII binding to TRRAP,
MYC was also shown bind to INI1, a member of the SWI/SNF
ATP-dependent chromatin remodeling complex. This interaction
is mediated via MYC’s bHLH and Zip domains and INI1’s Rpt1
domain (Figure 1). As MYC’s bHLH domain is required for its
transactivation function and binding to INI1, INI1 appears indis-
pensable for proper MYC function. Furthermore, intact SWI/SNF
complexes are also needed for MYC function. BRG1 is a functional
component of the SWI/SNF complex and its ATPase-defective
mutant abrogates histone remodeling activity and blocks tran-
scription of MYC targets (Cheng et al., 1999). It has also been
shown BRG1 can antagonize MYC transcriptional activation in
cancer models (Romero et al., 2012). While the results in tumor
models suggest BRG1 is necessary for maintenance of proper gene
expression and response to environmental stimuli, the abrogation
of BRG1 most likely blocks nucleosomal responses initiated not
only by MYC, but by other chromatin remodeling complexes
as well.
MYC ENHANCES TRANSCRIPTIONAL ACTIVATION
By the recruitment of HATs and the SWI/SNF complex, MYC can
remodel the nucleosomal topography to promote transcription.
But the question remains as to whether MYC can initiate tran-
scription. Results have shown that MYC cannot initiate de novo
transcription, but is necessary to maintain a nucleosomal land-
scape permissive for transcription (Knoepﬂer et al., 2006; Souﬁ
et al., 2012). Extensive chromosome immunoprecipitation and
sequencing (ChIP-Seq) analysis has revealed MYC E-box binding
is dependent on chromatin context. Without speciﬁc euchro-
matic islands characterized by methylated H3K4 and H3K79 and
acetylated H3, MYC is unable to access E-boxes on its target loci
(Guccione et al., 2006). Intriguingly, MYC also binds to euchro-
matic islands not on E-boxes, which may also explain MYC E-box
binding degeneracy.
In NB, a genome-wide assessment of MYCN using the Tetra-
cycline (TET) suppressible MYCN SHEP NB model system and
ChIP hybridizations to gene promoters (ChIP-Chip) revealed
that MYCN binding associates with euchromatic histone marks
H3K4me and H3K9Ac (Cotterman et al., 2008). The correlation
of MYCN binding and microarray analyses revealed that when
MYCN was induced, MYCN was found bound to genes that were
already transcriptionally active. MYCN was not associated with de
novo gene transcription. This is consistent with the recent mod-
els of MYC binding at or near transcription start sites (TSS) and
functioning to amplify transcription of actively transcribed genes
(Lin et al., 2012; Nie et al., 2012; Souﬁ et al., 2012). An interesting
aspect of the Cotterman’s study was the ﬁnding that upon loss
of MYCN expression there was a global loss of the euchromatic
marks even at sites that were not bound by MYCN (Cotterman
et al., 2008). This implies that MCYN plays a role in regulating
euchromatic regions in a manner that is independent of its role as
a classic transcription factor. One caveat raised in this study was
whether the assays were sufﬁciently sensitive to detect low afﬁnity
MYCN binding sites. The utilization of more sensitive and quan-
titative technologies such as MYCN ChIP-seq should clarify this
in the future.
MYC dependence on chromatin context is further supported
by studies revealing the temporal basis for chromatin remodeling.
During cellular reprogramming ectopic expression of transcrip-
tion factors can induce global chromatin changes as a cell reverts
from a differentiated state to a pluripotent state. Temporal anal-
ysis of reprogramming revealed that among the reprogramming
factors Oct4, Sox2, Klf4, and MYC (OSKM), only OSK can bind
to distal enhancer regions at an early time during reprogramming.
Subsequently MYC is recruited to the TSS to stabilize chromatin
binding and promote transcription. Furthermore, OSK proteins
are all able to bind to one side of the DNA helix, suggesting
they are able to bind to heterochromatic regions. MYC does not
bind to heterochromatic regions. MYC is predominantly found
on euchromatic regions indicating it requires a prior transcrip-
tional stimuli or de novo factors to bind to DNA to initiate its
transcriptional function (Souﬁ et al., 2012).
Since MYC cannot initiate de novo transcription, the question
arises as to how MYC can promote the induction of transcrip-
tion initiated by reprogramming factors. Regulation of gene
transcription in complex chromatin models is still evolving and
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occurs in at least ﬁve steps: (1) initiation, (2) promoter pausing,
(3) mRNA capping, (4) promoter escape, and (5) transcript
elongation. A clue to MYC function during initiation lies with
MYC binding to TBP (Figure 2D; McEwan et al., 1996). MYC
is a direct TBP binding partner and may be able to couple the
pre-initiation complex to its target promoters. Moreover, MYC
has been implicated at mRNA capping, promoter escape, and
elongation.
Until recently, the predominant or rate limiting mechanism
regulating initiation of transcription on gene promoters was
thought to be the bindingor loadingof Pol II onto targetDNAsites,
termed initiation. Pol II bound at promoters is marked by phos-
phorylation by TFIIH on serine 5 of its carboxy-terminal domain
(CTD), p-Ser5-Pol II. Genome-wide analyses of Pol II binding
demonstrated that p-Ser5-Pol II commonly resides at promoters
or is paused 20–40 bases downstream of the promoters of many
non-expressed genes. The capping machinery is recruited to the
CTD of Pol II and results in the addition of a methylated guanine
at the 5′-triphosphate of the nascent mRNA strand. MYC also
binds to TFIIH and the increased p-Ser5-Pol II increases capping
associated methylation. Capping is required for the recruitment
of the translation machinery and mRNA binding to ribosomes.
The acetylated lysine binding bromodomain containing protein
BRD4, recruits P-TEFb complex which phosphorylates serine 2
on the CTD region of Pol II (p-Ser2-Pol II) causing elongation of
mRNA transcripts and promoter escape (Figure 2D; Rahl et al.,
2010). MYC also binds to P-TEFb enhancing P-TEFb kinase activ-
ity.WhileMYCeffects on transcriptional elongation aredependent
on its DNA binding activity, evidence indicates that MYC effects
on capping are independent of its DNA binding activity (Cole and
Cowling, 2008; Cowling and Cole, 2010).
By studying reciprocal events in differentiation and reprogram-
ming the progression from transcriptional initiation to elongation
canbe extrapolated andpathologic consequences canbe evaluated.
During reprograming OSK function much like pioneering fac-
tors during embryonic development and differentiation. Pioneer
factors initially bind to heterochromatic regions and then recruit
cofactors and other transcription factors to initiate transcrip-
tion (Cirillo et al., 2002; Zaret and Carroll, 2011). MYC would
then be recruited to promoter regions to reinforce the permis-
sive chromatin state. In neural progenitors loss of MYC results in
increased H3K9me2, a mark of repressive chromatin, decreased
acetylated H3 and H4, marks of active chromatin, and overall
chromatin condensation characterized by increased heterochro-
matin. The changes in histone architecture are also noted to be
cell cycle and differentiation independent, but higherMYC expres-
sion did correlate with increased nuclear size (Knoepﬂer et al.,
2006). This change in nuclear size can be seen in Figure 3A, in
which MYCN transfection into the NB cell line SK-N-AS (clone
14.2) results in cells with a relative nuclear size twice that of
the parental or control-transfected (8B) cell lines which con-
tain a single copy of MYCN and do not express MYCN mRNA
(Figure 3B). Decreased euchromatic regions have also been iden-
tiﬁed in tumor models when MYC is knocked down (Wu et al.,
2007). The results suggest MYC is essential in euchromatin main-
tenance after its initial recruitment. In this context, the importance
of MYC in neural progenitors may derive its importance from
stimulating transcription of nascent factors necessary for neu-
ral proliferation before being down-regulated to initiate terminal
differentiation.
MYC AND TRANSCRIPTIONAL REPRESSION
As a transcriptional ampliﬁer, transcripts targeted by MYC would
be expected to be up-regulated, but there remains a sizeable cohort
of down-regulatedMYC targets. MYCdoes not bind to corepressor
complexes, so it is reasonable to surmise the down-regulated genes
are secondary or indirect effects of MYC function. A recent study
by Valentijn et al. (2012) identiﬁed a MYCN gene signature set in
NB cell lines of 157 genes in which a subset was transcriptionally
repressed genes (Valentijn et al., 2012). ChIP analyses on promoter
arrays indicated that MYCN exhibited relatively weaker binding to
the TSS of repressed genes compared to binding at the TSS of
FIGURE 3 | MYCN influences global chromatin structure. (A)The SK-N-AS
cell line contains a single copy of MYCN and does not express signiﬁcant
quantities. Upon transfection of SK-N-AS with MYCN (14-2, Vector control:
8B), one can see enlarged nuclei in high MYCN expressing cells (nuclei are
stained with DNA binding dye DAPI). (B) Measurements indicate a twofold
increase in nuclear size.
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up-regulated genes. This is consistent with the recent MYC ChIP-
seq studies that didnot ﬁndMYCbinding toTSSof genes repressed
by MYC expression (Lin et al., 2012; Nie et al., 2012).
Early models of transcriptional suppression associated with
MYC and MYCN involve an indirect mechanism in which
MYC/MAX dimers compete with other bHLH-Zip transcription
factors for E-box binding to alter target gene activity. For example
the MYC antagonist MAD also has chromatin modifying abilities
that may explain how it can modulate MYC function. MAD is
able to recruit histone deacetylases (HDACs), via SIN3 a tran-
scriptional corepressor, to target loci to induce transcriptional
silencing (Laherty et al., 1997; Ayer, 1999; Knoepﬂer and Eisen-
man, 1999). Thus the model arises where MYC/MAX recruit
HATs to induce chromatin acetylation making it more permissive
for transcription and MAD/MAX recruit HDACs to deacetylate
chromatin thereby silencing transcription (Figure 2B). In NB,
the combined treatment of RA and Interferon-gamma (INF-γ)
has been shown to dramatically decrease cell growth and induce
differentiation (Lucarelli et al., 1995). It was recently shown that
the transcriptional repression of two genes associated with the
growth of NB cells, ornithine decarboxylase (ODC) and human
telomerase reverse transcriptase (hTERT) was associated with a
shift in promoter occupancy of MYCN/MAX binding at steady-
state to MAD/MAX binding after RA and INF-γ treatment. This
results in a decrease in H4 acetylation at these promoters and
decreased expression of ODC and hTERT mRNA (Cetinkaya et al.,
2007). The precise levels of activation and silencing probably
exist in stoichiometric balance and are dependent on environ-
mental and cellular mechanisms regulating MYC and MAD
expression.
Another model of MYCN-mediated transcriptional repres-
sion invokes the association of MYC binding to the MIZ and
SP1 transcriptional activators resulting in the recruitment of
HDACs. This has been demonstrated for two genes associated
with good prognosis and differentiation in NB, NTRK1(TrkA),
and p75(NGFR). Upon induction of MYCN, there is increased
HDAC1 and decreased acetylated H3 binding over the TSS of these
promoters. The functional presence of MYCN was found to atten-
uate their promoter activity (Iraci et al., 2011). One can see how
the increased levels of MYCN that accompanies gene ampliﬁcation
would disrupt normal cellular transcription factor stoichiometry
leading to aberrant gene regulation.
Most recently MYC has been found to transcriptionally amplify
epigenetic modiﬁers with transcriptional repressive activities. For
example, in ESCsMYC stimulates all components of the polycomb
repressive complex 2 (PRC2), including embryonic ectoderm
development (Eed), suppressor of zeste 12 (Suz12), and his-
tone methyltransferase enhancer of zeste homolog 2 (EZH2), in
ESCs (Zhang et al., 2005; Neri et al., 2012). PRC2 functions to
epigenetically silence gene expression, but at a different histone
residue. PRC2 catalyzes trimethylation of H3K27 (H3K27me3).
It is believed that the persistent H3K27me3 at particular gene
loci results in the recruitment of the PRC1 complex to induce
chromatin compaction (reviewed in Bernstein et al., 2007; Simon
and Kingston, 2009). In NB relatively high levels of EZH2 are
associated with undifferentiated NB tumors (Wang et al., 2012).
The dysregulation of EZH2 may be due to a number of factors
including MYCN, increased chromosome 7 copy number or loss
of a regulator miR-101, which resides on 1p36. Functionally EZH2
was reported to suppress a number of genes with tumor sup-
pressor activity in NB including the MYCN-regulated genes CLU
and p75(NGFR). Enhanced EZH2 and it target H3K27me3 bind-
ing were detected at potential MYCN binding sites at steady-state
conditions but the addition of an HDAC inhibitor was associated
with decreased EZH2 and H3K27me3 binding and increased CLU
and p75 expression (Wang et al., 2012). It is not known whether
PRC2 complex components directly bind to MYC/MYCN but the
enhanced binding of EZH2 and H3K27me3 covered an E-box in
the CLU promoter and was over the TSS area identiﬁed to bind
MYCN in the p75(NGFR) promoter (Iraci et al., 2011).
Furthermore, in NB cell lines and tumor samples, MYCN stim-
ulates B cell-speciﬁc Moloney murine leukemia virus integration
site (BMI1) expression. BMI1 is a member of the PRC1 com-
plexwhose targets are oftenhypermethylated suggesting epigenetic
silencing (Ochiai et al., 2010). As part of a suppressive complex,
BMI1 has been shown to repress tumor suppressor genes and cat-
alyze events leading toNB tumorigenesis. BMI1 is highly expressed
in NB cell lines and NB tumor samples and was shown to have
anti-apoptotic effects via stimulation of RING1A/B ubiquitin-
mediated degradation of P53 (Cui et al., 2007; Calao et al., 2012).
The pro-survival effects of BMI1 suggestMYCN induction leads to
greater chances for tumor initiating events. Beyond BMI1’s tran-
scriptional targets in NB, PRC1 has also been shown to inhibit the
transcriptional pre-initiation complex thereby inhibiting Pol II-
mediated transcription (Lehmann et al., 2012). The summation
of the events suggests BMI1/PRC1 suppress active transcrip-
tion and catalyze epigenetic silencing, which may lead to NB
tumorigenesis.
Given MYCN’s role in stimulating expansion of neural progen-
itors, it is not unexpected that differentiation genes like NTRK1
or p75(NGFR) are repressed by MYCN. A global survey by ChIP-
Chip of ESCs for MYC and Miz-1 binding sites indicated that
almost 30% of Miz-1-regulated genes could be repressed by MYC.
These included homeobox genes, developmental proteins and
genes involved in regulation of apoptosis. In NB tumor samples,
within the MYCN gene signature set, 30% of the down-regulated
genes in the set are neuronal tissue-speciﬁc genes while only 2%
of such genes are up-regulated (Valentijn et al., 2012). This is
consistent with one of the ﬁrst studies on MYCN regulation in
NB cells which indicated that retinoid mediated down-regulation
of MYCN occurred prior to evidence of differentiation (Thiele
et al., 1985).
TARGETING MYC
Since MYC has been implicated in oncogenic transformation,
researchers and clinicians have sought to target MYC and its onco-
genic functions. A common mode of function of therapeutic
interest has been MYC’s chromatin remodeling and transcrip-
tional activities. It was rationalized that since MYC binds and
recruits coactivators containing the bromodomain and extrater-
minal (BET) members of human bromodomain proteins (BRD2,
BRD3, and BRD4), which associate with acetylated histones, it
could be functionally targeted (Dey et al., 2003; Delmore et al.,
2011). This interaction is mediated by P-TEFb, which facilitates
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics January 2013 | Volume 3 | Article 1 | 6
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FIGURE 4 | Decrease of EZH2 affects NB cell growth and induces the
neurites (Wang et al., 2012). (A) Cell survival in KCNR cells after a 3-day
infection with EZH2 or non-target shRNA lentivirus was assessed using a
Cell-Titer Blue assay (left). The percentage of surviving cells was normalized
by the absorbance value of the non-target shRNA-infected cells (control).
Representative images (×200) of the non-target shRNA-infected cells (ctrl,
middle), EZH2 shRNA–infected cells (EZH2 shRNA, right). (B) KCNR cells
were treated with different concentration of DZNep for 96 h. MTS assay was
used to detected cell survival (left). The percentage of surviving cells was
normalized by the absorbance value of the non-treated cells. Representative
images (×200) of the non-treated cells (ctrl, middle) and 0.5 μmol/L
DZNep-treated cells (DZNep 0.5 μmol/L, right). (C) KCNR cells were treated
with different concentration of DZNep for 96 h. The cells were stained with
propidium iodide and analyzed by ﬂow cytometry. The data showed
percentage of events in sub-G1, G1, and S/G2–M phase. (D) Caspase
3/7 activities were assessed after 48 h with different concentration of
DZNep in KCNR cells. The percentage of caspase 3/7 activity was graphed
after normalization to non-treated cells. (E) KCNR cells were treated with
5 μmol/L DZNep in the absence or presence of 100 μmol/L pan caspase
inhibitor, Z-VAD-FMK, for 72 h. The percentage of surviving cells was
graphed after normalization to untreated control. (F) Mice were treated with
or without DZNep (2.5 mg/kg) twice a day, 3 days per week for 4 weeks.
The mean tumor volumes are plotted using the SEM.The time points with
signiﬁcant differences (P < 0.05) are indicated with an asterisk. Adapted
fromWang et al. (2012). © 2012 American Association for Cancer
Research.
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transcriptional elongation and Pol II promoter pause release (Bis-
grove et al., 2007; Rahl et al., 2010). To target MYC function, JQ1
a small molecule inhibitor of BET bromodomains was evaluated
for therapy. In multiple myeloma, which is characterized by chro-
mosomal aberrations including MYC ampliﬁcation, JQ1 showed
signiﬁcant effects in abrogating MYC oncogenic function and also
reduced MYC expression (Delmore et al., 2011). JQ1 has also been
shown to have anti-proliferative effects in acute lymphoblastic
leukemia (Ott et al., 2012). While, JQ1 has shown promise in tar-
getingMYC,other inhibitors of MYCdownstream targetsmay also
be of therapeutic interest.
As MYC and MYCN have been shown to induce EZH2 expres-
sion and activity (Zhang et al., 2005; Neri et al., 2012) it is
reasonable to assume that this also occurs in NB tumors. Targeting
EZH2 may be another avenue to more robustly de-repress a subset
of genes suppressed due to MYCN stimulation of EZH2. In NB
cells inhibition of MYCN expression by targeted small interfering
RNAs (siRNAs) leads to decreases in EZH2 protein levels which
is accompanied by a decrease in the global levels of H3K27me3
(Figure 4; Wang et al., 2012). The importance of targeting EZH2
in NB was ﬁrst noted with our ﬁnding that targeted inhibition
of EZH2 leads to induction of genes having tumor suppressive
or differentiation inducing capacity (Wang et al., 2012). In this
study, targeted inhibition of EZH2 using shRNA (Figure 4A)
or a small molecule inhibitor of EZH2, 3-Deazaneplanocin A
(DZNep; Figure 4B) led to decreased growth and induction of
neurites. Mechanistically this was also accompanied by induc-
tion of cell death (Figure 4C) which was due to increased levels
of activated caspase 3/7 activity (Figure 4D) since the apoptotic
effects of DZNep could be reversed by a caspase 3/7 inhibitor
(Figure 4E). The ﬁnding that DZNep inhibited the growth of NB
tumor xenografts is promising (Figure 4F). However, all mice still
succumbed to tumors suggesting that combination therapies may
be required to more efﬁcaciously block tumor growth.
MYC’s dysregulation of epigenetic writers, readers, or erasers
thus provides a novel avenue that can be therapeutically devel-
oped sincemanyof these proteins have targetable enzyme activities
(Lawlor and Thiele, 2012).
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